Enochian Biosciences (OTCMKTS:ENOB) Stock Price Up 10.9%

Enochian Biosciences Inc (OTCMKTS:ENOB)’s share price rose 10.9% during trading on Wednesday . The stock traded as high as $6.20 and last traded at $5.28, approximately 117,524 shares changed hands during mid-day trading. An increase of 138% from the average daily volume of 49,381 shares. The stock had previously closed at $4.76.

The company has a 50 day simple moving average of $4.65 and a 200 day simple moving average of $5.73.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Enochian Biosciences by 5.3% in the second quarter. Vanguard Group Inc. now owns 535,607 shares of the company’s stock valued at $2,411,000 after purchasing an additional 27,039 shares during the last quarter. BlackRock Inc. boosted its holdings in Enochian Biosciences by 316.8% in the second quarter. BlackRock Inc. now owns 221,718 shares of the company’s stock valued at $998,000 after purchasing an additional 168,520 shares during the last quarter. Susquehanna International Group LLP purchased a new position in Enochian Biosciences in the second quarter valued at about $133,000. United Capital Financial Advisers LLC purchased a new position in Enochian Biosciences in the second quarter valued at about $105,000. Finally, Wells Fargo & Company MN purchased a new position in Enochian Biosciences in the second quarter valued at about $72,000.

About Enochian Biosciences (OTCMKTS:ENOB)

Enochian Biosciences Inc, a biopharmaceutical company, identifies, develops, manufactures, and commercializes gene therapies for HIV/AIDS and cancer patients. Its lead candidate include ENO-1001 a genetically modified cell therapy for patients with HIV/AIDS. It is also developing ENO-2001, an HIV vaccine; and additional compounds, such as ENO-4001, ENO-4002, ENO-3001, and ENO-5001 that are in discovery stage for prevention of relapse in colon cancer patients.

See Also: How does equity income fit into an investing strategy?

Receive News & Ratings for Enochian Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enochian Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit